Bristol Myers’ Opdivo with Exelixis drug cuts kidney cancer death risk: study NEW YORK (Reuters) – Bristol Myers Squibb Co’s cancer immunotherapy Opdivo in combination with Exelixis Inc’s Cabometyx reduced […]

A Phase III trial is planned after promising results were revealed from Dana-Farber Cancer Institute for MK-6482 in advanced clear cell kidney cancer.

New clinical data shows that Eli Lilly’s investigational oncology drug pegilodecakin, in combination with a checkpoint inhibitor, could be a potential new treatment for patients with non-small cell lung cancer and kidney cancer.

U.S. drugmaker Merck & Co. Inc. agreed to buy Peloton Therapeutics Inc. for $1.05 billion in cash, gaining access to the privately held company’s lead kidney cancer drug candidate.

The Food and Drug Administration approved Merck & Co.’s cancer therapy Keytruda as part of a combination therapy for previously untreated patients with the most common type of kidney cancer.

Nektar Therapeutics said some patients with advanced bladder cancer treated with a combination of the company’s experimental treatment and Bristol-Myers Squibb’s immunotherapy Opdivo showed signs of tumor reduction in an early-stage study.

Merck & Co. Inc. said the combination of the drugmaker’s cancer immunotherapy Keytruda with Pfizer Inc.’s Inlyta cut the risk of death nearly in half for patients with the most common form of kidney cancer when compared with treatment with the chemotherapy drug Sutent.

Shares of AVEO Oncology plunged 45 percent after the Cambridge, Mass.-based company accepted the recommendation of the U.S. Food and Drug Administration to not seek regulatory approval of the kidney cancer drug Tivozanib at this time.

Merck & Co.’s cancer drug Keytruda in combination with Pfizer Inc.’s Inlyta met the main goals of a late-stage study for the most common form of kidney cancer.

The J.P. Morgan Healthcare Conference is a yearly opportunity for the biopharma industry to make major announcements and allow analysts, investors and the media pick the brains of top execs. Here is a look at what four of the top big biopharma companies shared at the meeting.